TScan Therapeutics has started dosing the first participant in a Phase 1 study to assess TCR-T therapy against solid tumors.

Fate Therapeutics Reports Initial Treatment of a Lupus Patient in its Phase 1 Study for the FT819 CAR T-cell Off-the-shelf Therapy.

Acepodia Reveals Initial Results from Phase 1 Study of ACE1831, the First Anti-CD20 Antibody-Linked Allogeneic Gamma Delta T Cell Treatment for Non-Hodgkin’s Lymphoma.

This acquisition will not only enrich Novartis's research and development pipeline in Radioligand Therapy (RLT) but will also enhance the company’s research foundation and clinical supply capabilities in oncology and RLT platform innovations.

Sobi announced that the European Commission has approved Aspaveli® (pegcetacoplan) to treat adults with paroxysmal nocturnal haemoglobinuria and haemolytic anaemia.

Lenvatinib, marketed under the brand name Lenvima, is a multikinase inhibitor specifically targeting vascular endothelial growth factor (VEGF) receptors.

Phanes Therapeutics, Inc. has entered into a clinical supply deal with Roche to test PT217 alongside an anti-PD-L1 treatment.

Adjuvants are substances used in vaccines to enhance the body's immune response to an antigen.

Neurocrine Biosciences, Inc. has launched its Phase 1 clinical trial, marking the first time humans are being evaluated.

Tirofiban, marketed under the brand name Aggrastat, is a potent medication that belongs to the class of glycoprotein IIb/IIIa receptor inhibitors.

The disclosed CS5001 is an ADC targeting ROR1, featuring a unique design.

Adjuvants are substances that are added to vaccines to enhance the body's immune response to an antigen (a substance that can trigger an immune response).